Preventing low platelets from chemo in GI cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system clinical trials.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a GI cancer like esophageal, stomach, or colorectal cancer.
- You had a platelet count of at least 75 in your last chemo cycle AND had a bleeding risk factor (like past bleeding, certain chemo drugs, bone marrow involvement, or radiation).
- Your platelet count is at least 100 before starting a new chemo cycle.
- You are on a 14- or 21-day chemo cycle and need at least one more cycle.
- You have adequate kidney, liver, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
This trial tests a drug called romiplostim to prevent low platelet counts (a condition that raises bleeding risk) caused by chemotherapy in people with breast cancer. If you qualify, you may receive this drug to help keep your platelets at a safer level during future treatments.
This trial tests whether a drug called hetrombopag can prevent dangerously low platelet counts (cells that help blood clot) in breast cancer patients receiving chemotherapy. It is for people who experienced very low platelets from a previous round of treatment.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This study tests a medicine called hetrombopag that may help raise your platelet count after chemotherapy for advanced lung cancer. It aims to prevent dangerously low platelet levels so you can continue your cancer treatment more safely.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
Hear when a new Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.